MIP-2

Viral

E.coli

Viral Macrophage Inflammatory Protein II, vMIP-1B, MIP-II, vMIP-2

Viral MIP-2 is one of the three chemokine-like proteins expressed by the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV) and the other is ViMIP-1 and ViMIP-3. Viral MIP-II cDNA encodes a 94 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide that is cleaved to yield a 71 aa residue mature protein. It shares 41 % and 48 % with human MIP-1α and ViMIP-1, respectively. ViMIP-2 has been shown to have antagonist activity towards a wide range of chemokine receptors and has functions of blocking infection by several different human immunodeficiency virus type 1 (HIV-1) strains. It may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. Additionally, ViMIP-2 has been shown to activate and chemoattract human eosinphils.

Approximately 8.0 kDa.

LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA

Sterile Filtered White lyophilized (freeze-dried) powder.

>97% by SDS-PAGE and HPLC analyses

The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0 µg-10.0 µg/mL of viral MIP-2 will inhibit 25ng/mL of human MIP-1 alpha. Fully biologically active when compared to standard.

< 1.0 EU per 1μg of the protein by the LAL method.

Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH 7.4, 150mM NaCl.

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20℃. Further dilutions should be made in appropriate buffered solutions.

10, 100, 500μg